Clinical Advisors

Daniel D. Von Hoff, M.D., F.A.C.P. : Clinical Advisor

  • Mayo Clinic, TGen, US Oncology.
  • Physician in Chief, Distinguished Professor, Director of Clinical Translational Research Division at TGen;
  • CSO, US Oncology Research;
  • Professor of Medicine, Mayo Clinic, Scottsdale, AZ.
  • Recognized expert in Oncology drug development;
  • PI on numerous phase I-III clinical trials including Abraxane; >620 papers, 137 book chapters
  • 2010 David A. Karnofsky Memorial Award from ASCO; Past President of the AACR; Appointed to President Bush’s National Cancer Advisory Board in 2004-2010.
  • Founder of ILEX™ Oncology.

Sant Chawla, MD, FRACP : Advisor, Oncology Programs

  • Director, Sarcoma Oncology Center, Santa Monica, CA.
  • Academic appointments and affiliations: Stanford Univ Medical Center, MD Anderson Cancer Center, David Geffen School of Medicine UCLA, Keck School of Medicine USC, Cedars Sinai Medical Center
  • Extensive Clinical trial experience (>30 yrs) : Phase 1-3. Pazopanib, Denosumab, Ridoforolimus (rapamycin analog), Palifosfomide, Aldoxorubicin, TH302, belinostat, ofatumumab, AMG655, MEK162 and others

James McKiernan, MD : Columbia University Medical Center

  • Chair, Department of Urology
  • John and Irene Given Professor of Urology, Herbert Irving Comprehensive Cancer Center
  • Recognized expert in treatment of early stage bladder cancer
  • PI, AADI Bladder cancer Phase I/II trial
  • > 130 publications
  • Investigator in numerous clinical trials

Mark Gladwin, MD : University of Pittsburgh School of Medicine [PAH]

  • Chief of the Pulmonary, Allergy and Critical Care Medicine Division
  • Recognized expert in pulmonary hypertension and sickle cell disease
  • PI, AADI Pulmonary Hypertension Phase I/II trial
  • > 200 publications
  • Investigator in > 25 clinical trials

Clinical Advisors

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and other children living with treatment-resistant or intractable epilepsy. For reasons largely unknown, seizures in this subset of children persist long past their discovery in early childhood despite being treated with multiple medications and undergoing surgery to remove the affected parts of their brain. Diagnosed with epilepsy at age 5, life for Dameral has always come with seizures attached. When his seizures returned after a second brain surgery shortly after his 16th birthday, his mom Linley Allen, hoped for a medical breakthrough. “We needed to find something else since another surgery was out of the question,” Allen said. “We had heard about a drug being studied for a more severe seizure condition. I kept holding onto hope that it might be expanded to treat Shanny’s type of seizures because it was all we had at the time.”   See all and the original News article here: New Drug Trial Gives Hope for Treatment-Resistant Epilepsy